More than 85 percent of African-American men and women are likely to develop hypertension in their lifetimes based on the new cutoff for high blood pressure established in the 2017 U.S. guidelines, researchers reported March 27 in JAMA Cardiology.

Nearly 60 percent of patients who met guideline-based criteria for statin therapy but weren’t taking the cholesterol-lowering drugs said they were never offered one, according to a study published March 27 in the Journal of the American Heart Association.

In the largest-ever randomized trial of antihypertensive drug treatment in sub-Saharan Africa, two medication combinations including the long-acting calcium channel blocker amlodipine outperformed a third two-drug combination featuring a diuretic and an angiotensin-converting-enzyme (ACE) inhibitor.

Hypertensive patients from the RADIANCE-HTN SOLO trial who received renal denervation sustained a lower blood pressure through six months compared to participants randomized to a sham procedure, despite being placed on fewer antihypertensive medications during follow-up.

NEW ORLEANS — A new analysis considering not only a patient's first cardiovascular event—but the second, third and beyond—paints the REDUCE-IT trial in an even more positive light. 

The CDC has released a new fact sheet on the burden of chronic kidney disease (CKD) in the U.S., highlighting its relationship to cardiovascular disease and noting that 15 percent of American adults—or 37 million people—have CKD.

The FDA fast-tracked the approval process for a new generic valsartan product (Diovan) amid an ongoing shortage of the blood pressure and heart failure medication.

A napping habit could lower blood pressure to a similar extent as other lifestyle modifications and some drugs, according to research scheduled to be presented March 18 at the American College of Cardiology’s scientific sessions in New Orleans.